Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 106 people, all of whom received a drug called mirvetuximab soravtansine. The trial was measuring how the drug performed in participants with a specific type of ovarian cancer. The main thing researchers were tracking was the "objective response rate" — that is, the proportion of participants whose tumours shrank or disappeared by a defined amount during treatment. A number of secondary measures were also tracked, including how long any tumour shrinkage lasted, how long before the disease progressed, and how long participants survived overall. The reported data shows that 32.4% of participants (roughly 1 in 3) had their tumours shrink or disappear to a degree that met the trial's definition of a response. Among those who did respond, the reported duration of that response was a median of approximately 6.93 months (median means half lasted longer, half shorter). For a blood marker of ovarian cancer called CA-125, 46.5% of participants showed a meaningful reduction. The reported median progression-free survival — the time before the disease was recorded as worsening — was approximately 4.27 months, and the reported median overall survival was approximately 15.0 months. Regarding unwanted medical events during the trial, the reported data shows that 105 out of 106 participants experienced at least one treatment-emergent adverse event (an unintended medical occurrence that happened during or shortly after treatment); the nature and severity of those events are detailed separately in the trial's adverse events section on ClinicalTrials.gov. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 38858103) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Ovarian Cancer Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Women aged 18 or older
- People with a confirmed diagnosis of high-grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
- People whose cancer has become resistant to platinum-based chemotherapy in one of these ways: those who had one course of platinum treatment, responded to it, but saw the cancer come back between 3 and 6 months after the last dose; or those who had two or three courses of platinum treatment and saw the cancer come back during or within 6 months of the last dose
- People whose cancer has been shown on scans to have grown or spread after their most recent cancer treatment
- People willing to provide a stored tumour tissue sample, or to have a new low-risk biopsy taken, to check for a specific protein called Folate Receptor α (FRα)
- People whose tumour tests positive for the FRα protein using a specific approved test
- People who have at least one tumour that can be measured on a scan using standard criteria
- People who have received between 1 and 3 prior cancer treatments overall, including at least one treatment containing a drug called bevacizumab, and for whom a single-drug treatment is appropriate as the next step
- People with a good general level of physical functioning, rated 0 or 1 on a standard scale used by doctors (confirm with trial site)
- People who have finished their most recent cancer treatment within the required timeframes before starting the trial drug
- People whose side effects from previous treatments have mostly settled (back to mild or baseline levels), except for hair loss
- People who had major surgery at least 4 weeks before the trial and have recovered from it
- People with blood counts, kidney function, and liver function that meet the required levels as confirmed by blood tests
- People who are willing and able to sign a consent form and follow the trial requirements
- Women who could become pregnant and agree to use highly effective contraception during the trial and for at least 3 months after the last dose
- Women who could become pregnant and have a negative pregnancy test within 4 days before the first dose
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- Men
- People whose cancer is a type other than high-grade serous, such as endometrioid, clear cell, mucinous, or sarcomatous, or who have a low-grade or borderline ovarian tumour
- People whose cancer never responded to platinum-based chemotherapy, or came back within 3 months of finishing their first platinum treatment
- People who have had extensive radiation therapy covering a large area of the body affecting a significant portion of the bone marrow
- People with nerve damage in their hands or feet rated above mild (Grade 1) on a standard medical scale
- People with active or long-standing eye conditions such as uncontrolled glaucoma, certain types of macular degeneration, active diabetic eye disease, swelling of the optic nerve, single-eye vision, or a history of corneal transplant
- People with serious ongoing illness or active infection, including active hepatitis B or C, HIV, active cytomegalovirus infection, or any infection requiring intravenous antibiotics within 2 weeks before starting the trial
- People with a history of multiple sclerosis, other nerve-coating diseases, or Lambert-Eaton syndrome
- People with significant heart problems, including a heart attack within the past 6 months, unstable chest pain, poorly controlled heart failure, poorly controlled high blood pressure, or uncontrolled abnormal heart rhythms
- People who have had a stroke or bleeding in the brain within the past 6 months
- People with advanced liver scarring (cirrhosis rated as Child-Pugh Class B or C)
- People with a history of non-infectious lung inflammation (such as non-infectious interstitial lung disease or pneumonitis)
- People who need to take folate supplements (for example, due to folate deficiency)
- People who have previously had a serious allergic reaction to monoclonal antibody treatments
- People who are pregnant or breastfeeding
- People who have previously been treated with the trial drug (MIRV) or other treatments that target the FRα protein
- People with brain metastases that are untreated or currently causing symptoms
- People who have had another cancer diagnosed within the past 3 years (some exceptions may apply for certain very low-risk skin cancers or early-stage cancers — confirm with trial site)
- People with a known serious allergic reaction to the trial drug or any of its ingredients
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial contact details on record
Principal Investigator: Michael Method, MD, MPH, MBA, ImmunoGen, Inc.
Australian sites
This trial is not accepting new participants. These are the contact details ClinicalTrials.gov holds for it, kept here for reference. They are not an invitation to enrol, and the sites listed may no longer be running this trial.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, including 4 in Australia. They are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Objective Response Rate (ORR): Percentage of Participants With Objective Response as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
Other options
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.